Total Payments
$185,178
2024 Payments
$19.63
Companies
7
Transactions
197
Medicare Patients
14,262
Medicare Billing
$882,696
Payment Breakdown by Category
Research$181,025 (97.8%)
Consulting$3,880 (2.1%)
Food & Beverage$272.84 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $181,025 | 176 | 97.8% |
| Consulting Fee | $3,880 | 11 | 2.1% |
| Food and Beverage | $272.84 | 10 | 0.1% |
Payments by Type
Research
$181,025
176 transactions
General
$4,153
21 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AbbVie Inc. | $181,025 | 176 | $0 (2023) |
| Merck Sharp & Dohme Corporation | $3,911 | 13 | $0 (2020) |
| Grifols USA, LLC | $109.29 | 1 | $0 (2022) |
| Eisai Inc. | $50.31 | 3 | $0 (2018) |
| Medtronic USA, Inc. | $45.77 | 2 | $0 (2018) |
| Stryker Corporation | $19.63 | 1 | $0 (2024) |
| Celgene Corporation | $16.52 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $19.63 | 1 | Stryker Corporation ($19.63) |
| 2023 | $3,115 | 10 | AbbVie Inc. ($3,115) |
| 2022 | $5,274 | 16 | ABBVIE INC. ($5,165) |
| 2021 | $22,320 | 39 | ABBVIE INC. ($22,320) |
| 2020 | $41,800 | 55 | AbbVie Inc. ($40,840) |
| 2019 | $76,730 | 45 | AbbVie, Inc. ($75,410) |
| 2018 | $35,884 | 29 | AbbVie, Inc. ($34,175) |
| 2017 | $34.51 | 2 | Medtronic USA, Inc. ($21.03) |
All Payment Transactions
197 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/02/2024 | Stryker Corporation | MOLLI (Device) | Food and Beverage | In-kind items and services | $19.63 | General |
| Category: ENDOSCOPY | ||||||
| 05/23/2023 | AbbVie Inc. | ORILISSA (Drug) | — | Cash or cash equivalent | $80.00 | Research |
| Study: Long-Term Safety Study of Elagolix in Combination With Estradiol;Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women • Category: WOMENS HEALTH | ||||||
| 05/16/2023 | AbbVie Inc. | ORILISSA (Drug) | — | Cash or cash equivalent | $850.00 | Research |
| Study: Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain • Category: WOMENS HEALTH | ||||||
| 04/18/2023 | AbbVie Inc. | ORILISSA (Drug) | — | Cash or cash equivalent | $340.00 | Research |
| Study: Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain • Category: WOMENS HEALTH | ||||||
| 04/18/2023 | AbbVie Inc. | ORILISSA (Drug) | — | Cash or cash equivalent | $160.00 | Research |
| Study: Long-Term Safety Study of Elagolix in Combination With Estradiol;Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women • Category: WOMENS HEALTH | ||||||
| 03/23/2023 | AbbVie Inc. | ORILISSA (Drug) | — | Cash or cash equivalent | $340.00 | Research |
| Study: Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain • Category: WOMENS HEALTH | ||||||
| 03/21/2023 | AbbVie Inc. | ORILISSA (Drug) | — | Cash or cash equivalent | $80.00 | Research |
| Study: Long-Term Safety Study of Elagolix in Combination With Estradiol;Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women • Category: WOMENS HEALTH | ||||||
| 02/14/2023 | AbbVie Inc. | ORILISSA (Drug) | — | Cash or cash equivalent | $510.00 | Research |
| Study: Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain • Category: WOMENS HEALTH | ||||||
| 02/14/2023 | AbbVie Inc. | ORILISSA (Drug) | — | Cash or cash equivalent | $80.00 | Research |
| Study: Long-Term Safety Study of Elagolix in Combination With Estradiol;Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women • Category: WOMENS HEALTH | ||||||
| 01/24/2023 | AbbVie Inc. | ORILISSA (Drug) | — | Cash or cash equivalent | $595.00 | Research |
| Study: Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain • Category: WOMENS HEALTH | ||||||
| 01/24/2023 | AbbVie Inc. | ORILISSA (Drug) | — | Cash or cash equivalent | $80.00 | Research |
| Study: Long-Term Safety Study of Elagolix in Combination With Estradiol;Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women • Category: WOMENS HEALTH | ||||||
| 12/20/2022 | ABBVIE INC. | ORILISSA (Drug) | — | Cash or cash equivalent | $850.00 | Research |
| Study: Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain • Category: WOMENS HEALTH | ||||||
| 12/20/2022 | ABBVIE INC. | ORILISSA (Drug) | — | Cash or cash equivalent | $80.00 | Research |
| Study: Long-Term Safety Study of Elagolix in Combination With Estradiolx2FNorethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women • Category: WOMENS HEALTH | ||||||
| 12/06/2022 | ABBVIE INC. | ORILISSA (Drug) | — | Cash or cash equivalent | $240.00 | Research |
| Study: Long-Term Safety Study of Elagolix in Combination With Estradiolx2FNorethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women • Category: WOMENS HEALTH | ||||||
| 11/15/2022 | ABBVIE INC. | ORILISSA (Drug) | — | Cash or cash equivalent | $425.00 | Research |
| Study: Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain • Category: WOMENS HEALTH | ||||||
| 11/09/2022 | ABBVIE INC. | ORILISSA (Drug) | — | Cash or cash equivalent | $170.00 | Research |
| Study: Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain • Category: WOMENS HEALTH | ||||||
| 11/09/2022 | ABBVIE INC. | ORILISSA (Drug) | — | Cash or cash equivalent | $80.00 | Research |
| Study: Long-Term Safety Study of Elagolix in Combination With Estradiolx2FNorethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women • Category: WOMENS HEALTH | ||||||
| 10/06/2022 | ABBVIE INC. | ORILISSA (Drug) | — | Cash or cash equivalent | $680.00 | Research |
| Study: Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain • Category: WOMENS HEALTH | ||||||
| 10/06/2022 | ABBVIE INC. | ORILISSA (Drug) | — | Cash or cash equivalent | $80.00 | Research |
| Study: Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women • Category: WOMENS HEALTH | ||||||
| 09/23/2022 | ABBVIE INC. | ORILISSA (Drug) | — | Cash or cash equivalent | $480.00 | Research |
| Study: Long-Term Safety Study of Elagolix in Combination With Estradiolx2FNorethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women • Category: WOMENS HEALTH | ||||||
| 09/01/2022 | ABBVIE INC. | ORILISSA (Drug) | — | Cash or cash equivalent | $320.00 | Research |
| Study: Long-Term Safety Study of Elagolix in Combination With Estradiolx2FNorethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women • Category: WOMENS HEALTH | ||||||
| 09/01/2022 | ABBVIE INC. | ORILISSA (Drug) | — | Cash or cash equivalent | $255.00 | Research |
| Study: Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain • Category: WOMENS HEALTH | ||||||
| 07/28/2022 | ABBVIE INC. | ORILISSA (Drug) | — | Cash or cash equivalent | $850.00 | Research |
| Study: Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain • Category: WOMENS HEALTH | ||||||
| 07/28/2022 | ABBVIE INC. | ORILISSA (Drug) | — | Cash or cash equivalent | $160.00 | Research |
| Study: Long-Term Safety Study of Elagolix in Combination With Estradiolx2FNorethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women • Category: WOMENS HEALTH | ||||||
| 07/27/2022 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Food and Beverage | In-kind items and services | $109.29 | General |
| Category: Pulmonology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| M16-283 | AbbVie, Inc. | $57,130 | 17 |
| M14-702 | AbbVie, Inc. | $31,365 | 17 |
| M16-837 | AbbVie Inc. | $15,290 | 13 |
| M14-702 | AbbVie Inc. | $12,920 | 13 |
| M12-816 | AbbVie, Inc. | $12,735 | 12 |
| A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain | ABBVIE INC. | $8,330 | 13 |
| M16-824 | AbbVie Inc. | $6,400 | 11 |
| A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain | ABBVIE INC. | $5,780 | 10 |
| M16-283 | AbbVie Inc. | $5,490 | 13 |
| A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women | ABBVIE INC. | $4,800 | 12 |
| Phase 2, Multicenter, Double-blind (Sponsor-unblinded), Randomized, Placebo-Controlled Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome | ABBVIE INC. | $3,410 | 4 |
| M16-824 | AbbVie, Inc. | $3,400 | 3 |
| M12-817 | AbbVie, Inc. | $2,850 | 5 |
| Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain | AbbVie Inc. | $2,635 | 5 |
| Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain | ABBVIE INC. | $2,550 | 5 |
| M12-815 | AbbVie, Inc. | $1,935 | 4 |
| Long-Term Safety Study of Elagolix in Combination With Estradiolx2FNorethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women | ABBVIE INC. | $1,600 | 7 |
| Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain | ABBVIE INC. | $935.00 | 2 |
| M18-969 | AbbVie Inc. | $740.00 | 2 |
| Long-Term Safety Study of Elagolix in Combination With Estradiol;Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women | AbbVie Inc. | $480.00 | 5 |
| M16-383 | AbbVie, Inc. | $170.00 | 2 |
| Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women | ABBVIE INC. | $80.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 3,113 | 13,710 | $534,292 | $156,088 |
| 2022 | 9 | 2,507 | 15,147 | $1.3M | $278,246 |
| 2021 | 9 | 2,669 | 12,812 | $1.0M | $233,988 |
| 2020 | 11 | 5,973 | 6,042 | $565,592 | $214,373 |
Total Patients
14,262
Total Services
47,711
Medicare Billing
$882,696
Procedure Codes
52
All Medicare Procedures & Services
52 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 77049 | Mri scan of both breasts | Office | 2023 | 214 | 394 | $223,498 | $60,930 | 27.3% |
| 77067 | Screening mammography | Office | 2023 | 1,061 | 1,082 | $154,591 | $42,574 | 27.5% |
| 77063 | Screening 3d breast mammography | Office | 2023 | 1,052 | 1,073 | $80,407 | $32,311 | 40.2% |
| 77065 | Diagnostic mammography of 1 breast | Office | 2023 | 119 | 121 | $15,985 | $3,462 | 21.7% |
| 77067 | Screening mammography | Facility | 2023 | 83 | 83 | $8,437 | $2,898 | 34.4% |
| A9585 | Injection, gadobutrol, 0.1 ml | Office | 2023 | 181 | 10,552 | $10,552 | $2,773 | 26.3% |
| 77066 | Diagnostic mammography of both breasts | Office | 2023 | 74 | 74 | $10,973 | $2,745 | 25.0% |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | Office | 2023 | 120 | 121 | $9,413 | $2,708 | 28.8% |
| 77063 | Screening 3d breast mammography | Facility | 2023 | 83 | 83 | $6,601 | $2,302 | 34.9% |
| 76642 | Limited ultrasound scan of 1 breast | Office | 2023 | 65 | 66 | $7,818 | $1,663 | 21.3% |
| 76641 | Complete ultrasound scan of 1 breast | Office | 2023 | 15 | 15 | $1,995 | $551.39 | 27.6% |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | Facility | 2023 | 20 | 20 | $1,344 | $444.00 | 33.0% |
| 77065 | Diagnostic mammography of 1 breast | Facility | 2023 | 14 | 14 | $1,511 | $412.86 | 27.3% |
| 76642 | Limited ultrasound scan of 1 breast | Facility | 2023 | 12 | 12 | $1,166 | $313.37 | 26.9% |
| 77067 | Screening mammography | Office | 2022 | 955 | 1,822 | $830,106 | $135,851 | 16.4% |
| 77049 | Mri scan of both breasts | Office | 2022 | 187 | 370 | $236,887 | $61,012 | 25.8% |
| 77063 | Screening 3d breast mammography | Office | 2022 | 935 | 1,797 | $95,895 | $54,315 | 56.6% |
| 77065 | Diagnostic mammography of 1 breast | Office | 2022 | 92 | 184 | $86,080 | $9,781 | 11.4% |
| 77066 | Diagnostic mammography of both breasts | Office | 2022 | 33 | 64 | $35,855 | $4,508 | 12.6% |
| 76641 | Complete ultrasound scan of 1 breast | Office | 2022 | 34 | 67 | $17,722 | $4,221 | 23.8% |
| 76642 | Limited ultrasound scan of 1 breast | Office | 2022 | 53 | 105 | $27,096 | $4,142 | 15.3% |
| A9585 | Injection, gadobutrol, 0.1 ml | Office | 2022 | 182 | 10,667 | $10,667 | $2,803 | 26.3% |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | Office | 2022 | 36 | 71 | $3,615 | $1,611 | 44.6% |
| 77067 | Screening mammography of both breasts | Office | 2021 | 885 | 1,439 | $559,945 | $100,117 | 17.9% |
| 77049 | Mri of both breasts with and without contrast | Office | 2021 | 167 | 324 | $185,365 | $56,176 | 30.3% |
About Dr. Hope Peters, MD
Dr. Hope Peters, MD is a Diagnostic Radiology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1790757193.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Hope Peters, MD has received a total of $185,178 in payments from pharmaceutical and medical device companies, with $19.63 received in 2024. These payments were reported across 197 transactions from 7 companies. The most common payment nature is "" ($181,025).
As a Medicare-enrolled provider, Peters has provided services to 14,262 Medicare beneficiaries, totaling 47,711 services with total Medicare billing of $882,696. Data is available for 4 years (2020–2023), covering 52 distinct procedure/service records.
Ad
Practice Information
- Specialty Diagnostic Radiology
- Location Boston, MA
- Active Since 02/02/2006
- Last Updated 09/12/2012
- Taxonomy Code 2085R0202X
- Entity Type Individual
- NPI Number 1790757193
Products in Payments
- Orilissa (Drug) $94,475
- ORILISSA (Drug) $71,440
- MK-8962 (Biological) $3,880
- Prolastin-C Liquid (Biological) $109.29
- Lenvima (Drug) $50.31
- Intact (Device) $24.74
- AQUAMANTYS (Device) $21.03
- MOLLI (Device) $19.63
- Abraxane (Drug) $16.52
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Diagnostic Radiology Doctors in Boston
Andrew Kompel, M.d, M.D
Diagnostic Radiology — Payments: $3.4M
Diagnostic Radiology $3.4M
Gregg Miller, M.d, M.D
Diagnostic Radiology — Payments: $3.0M
Diagnostic Radiology $3.0M
Stephan Anderson, M.d, M.D
Diagnostic Radiology — Payments: $2.4M
Diagnostic Radiology $2.4M
Ashraf Thabet, M.d, M.D
Diagnostic Radiology — Payments: $1.7M
Diagnostic Radiology $1.7M
Dr. Mukesh Harisinghani, Md, MD
Diagnostic Radiology — Payments: $1.4M
Diagnostic Radiology $1.4M
Subba Digumarthy, Md, MD
Diagnostic Radiology — Payments: $1.1M
Diagnostic Radiology $1.1M